Clinical efficacy and safety of liposomal doxorubicin in treatment of cancer: A systematic review / 药物评价研究

ABSTRACT

Objective To evaluate the clinical efficacy and safety of liposomal doxorubicin in the treatment of cancer.Methods The randomized controlled trials of liposomal doxorubicin in treatment of cancer were searched from Chinese academic literature database (CNKI),Wanfang digital joumals,Chinese biomedical literature database (CBM),Chinese scientific journal database (VIP),PubMed database,Embase database and The Cochrane Library database.Data were collected from establishment of the database to January 2017 and the each index was analyzed by Meta-analysis with RevMan 5.3 software.Results A total of 5546 patients with malignant tumors were included in the RCT literature of the 23 articles.The Meta analysis results showed that the analysis on clinical curative effect before and after treatmentI2 =63％,OR =1.14[1.02,1.27],P =0.002;the analysis on safety evaluation of Meta of two groups of cardiac toxicity adverse eventsI2=0％,OR =0.18[0.10,0.33],P ＜ 0.00001;I2=77％,OR =0.24[0.17,0.35];the analysis on alopecia adverse eventsP ＜ 0.000 01;I2=46％ OR=0.65[0.42,0.99],the ananlysis on neurotoxic adverse eventsP =0.05.Conclusion The clinical efficacy of liposomal doxorubicin in the treatment of malignant tumors is better than other chemotherapy regimens,with low side effects,and is especially significantly better than other chemotherapy regimens in the improvement of cardiac toxicity,neurotoxicity,alopecia and other adverse events.